Skip to Content
Morningstar

Harmony Biosciences Holdings Inc Ordinary Shares HRMY

Morningstar Rating
Unlock
Stock XNAS Rating as of
$28.86 −0.50 (1.70%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
HRMY is trading within a range we consider fairly valued.
Price
$29.24
Fair Value
$41.31
Uncertainty
Very High
1-Star Price
$53.92
5-Star Price
$97.62
Economic Moat
Jtmvsx
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HRMY is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$29.36
Day Range
$28.78–29.26
52-Week Range
$18.63–39.24
Bid/Ask
$28.80 / $28.86
Market Cap
$1.64 Bil
Volume/Avg
66,688 / 360,163

Key Statistics

Price/Earnings (Normalized)
8.73
Price/Sales
2.83
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
6.00%

Company Profile

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
246
Website
https://www.harmonybiosciences.com

Comparables

Valuation

View More
Metric
HRMY
CBAY
PLRX
Price/Earnings (Normalized)
 8.73——
Price/Book Value
 3.2412.651.54
Price/Sales
 2.83111.012,698.15
Price/Cash Flow
 8.87——
Price/Earnings
HRMY
CBAY
PLRX

Financial Strength

Metric
HRMY
CBAY
PLRX
Quick Ratio
 2.9310.7015.95
Current Ratio
 3.1110.9616.12
Interest Coverage
 7.56−5.27−138.69
Quick Ratio
HRMY
CBAY
PLRX

Profitability

Metric
HRMY
CBAY
PLRX
Return on Assets (Normalized)
 25.34%−30.06%−23.39%
Return on Equity (Normalized)
 41.43%−51.97%−25.61%
Return on Invested Capital (Normalized)
 30.24%−30.87%−29.08%
Return on Assets
HRMY
CBAY
PLRX
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
SrbpxrcjsRkvr$626.5 Bil
 Vertex Pharmaceuticals Inc
VRTX
RkflhzlBqvgh$122.2 Bil
 Regeneron Pharmaceuticals Inc
REGN
ZxhnvqfKdqsndt$115.2 Bil
 Moderna Inc
MRNA
JshmpzmrPsrv$52.8 Bil
 argenx SE ADR
ARGX
XlhwyxcVclk$22.6 Bil
 BioNTech SE ADR
BNTX
XfvvpqgXlh$21.3 Bil
 Alnylam Pharmaceuticals Inc
ALNY
FgsrmbhrMqtjgd$19.9 Bil
 Biomarin Pharmaceutical Inc
BMRN
RhhlwntykLjgyrg$16.1 Bil
 United Therapeutics Corp
UTHR
PdstwvhSfp$13.2 Bil
 Incyte Corp
INCY
WgnwwvqDgxxtc$12.4 Bil

Sponsor Center